Published in Cancer Res on May 01, 1988
A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs (2007) 0.91
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol (1989) 2.19
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Acne arthralgia. J Bone Joint Surg Am (1976) 1.90
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med (1977) 1.70
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res (1983) 1.47
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med (1968) 1.45
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res (1981) 1.45
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst (1996) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther (1980) 1.21
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res (1980) 1.20
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg (2001) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med (1980) 1.18
Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma. Lancet (1971) 1.18
Lung cancer: diagnosis in metastatic sites. Semin Oncol (1974) 1.17
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst (1993) 1.15
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res (1979) 1.14
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med (1969) 1.11
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Hypercalcemia associated with neoplastic disease. Ann Intern Med (1970) 1.10
Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res (1999) 1.09
Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol (1989) 1.08
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg (1980) 1.08
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology (2000) 1.08
Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res (1982) 1.08
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol (1992) 1.08
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer (1981) 1.07
Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer (1995) 1.06
Differences in the behavior of the membrane and membrane-associated filamentous structures in normal and chronic lymphocytic leukemia (CLL) lymphocytes. J Immunol (1979) 1.04
Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol (2001) 1.04
Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) (1981) 1.02
Adrenal suppression after short-term corticosteroid therapy. Lancet (1979) 1.02
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol (1984) 1.02
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer (2001) 1.01
Pulmonary toxicity of antitumor agents. Cancer Treat Rev (1983) 1.00
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med (1985) 0.99
Solution behavior, circular dichroism and 22 HMz PMR studies of the bovine myelin basic protein. Biochim Biophys Acta (1975) 0.98
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res (1997) 0.95
Long-term survivors with small cell carcinoma of the lung. Eur J Cancer (1980) 0.95
Decreased actin content of lymphocytes from patients with chronic lymphocytic leukemia. Blood (1982) 0.95
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol (1985) 0.94
The rediscovery of DON (6-diazo-5-oxo-L-norleucine). Recent Results Cancer Res (1980) 0.94
Cell kinetic studies in patients with small cell carcinoma of the lung. Cancer (1974) 0.94
Glomerulonephritis or nephrotic syndrome in malignant lymphoma, reticulum-cell type. Lancet (1971) 0.93
The chemotherapy of Hodgkin's disease: past experiences and future directions. Cancer (1978) 0.93
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol (1992) 0.93
Human B lymphocytes show greater susceptibility to H2O2 toxicity than T lymphocytes. J Immunol (1984) 0.93
Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol (1995) 0.92
A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol (1998) 0.92
Doxil in breast cancer. J Clin Oncol (1998) 0.90
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy. J Clin Oncol (1990) 0.90
Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Response Mod (1990) 0.90
Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma. J Clin Oncol (1985) 0.90
A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer (1995) 0.89
The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol (1985) 0.89
Treatment of small cell undifferentiated carcinoma of the lung: update of recent results. Cancer Treat Rep (1981) 0.89
Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep (1972) 0.89
Exploratory laparotomy in reticulum cell sarcoma. A retrospective analysis. Cancer (1972) 0.89
Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation. Cancer Chemother Rep (1975) 0.89
The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology (1973) 0.88
Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol (1979) 0.88